Sequencing Strategies and the Role of Combination Therapy
Panelists discuss how evolving treatment pathways at Emory Healthcare, including earlier use of emerging therapies and off-label combination treatments, are shaping the management of chronic graft-vs-host disease (cGVHD), with an emphasis on personalizing therapy based on real-world data and patient-specific factors.
Read More
Emerging Data: Impacts of ROCKstar and AGAVE-201
Panelists discuss how factors such as patient preferences, disease severity, organ-specific involvement, and adverse effect profiles influence the selection of second-line therapies for steroid-refractory chronic graft-vs-host disease (cGVHD) in the context of multiple FDA-approved agents.
Read More
Tailoring Therapy: Weighing Evidence, Organ Involvement, and Route of Administration
Panelists discuss how factors such as patient preferences, disease severity, organ-specific involvement, and adverse effect profiles influence the selection of second-line therapies for steroid-refractory chronic graft-vs-host disease (cGVHD) in the context of multiple FDA-approved agents.
Read More
Steroid-Refractory cGVHD: A Look at FDA-Approved Options
Panelists discuss how recent FDA approvals and evolving evidence for second-line treatments, including ruxolitinib, ibrutinib, and belumosudil, are reshaping chronic graft-vs-host disease (cGVHD) management by offering tailored, evidence-based options for steroid-refractory patients.
Read More
Navigating the Path to Second-Line Therapy
Panelists discuss how second-line therapy selection and individualized care strategies are essential in chronic graft-vs-host disease (cGVHD) management, emphasizing the need to reduce steroid-related toxicity, address patient-specific factors, and leverage pharmacist expertise to optimize outcomes.
Read More
Early Challenges in the cGVHD Journey
Panelists discuss how early diagnosis, evolving treatment strategies, and pharmacist-led interventions are advancing chronic graft-vs-host disease (cGVHD) management by addressing unmet needs, improving care coordination, and enhancing patient access to emerging therapies.
Read More